632 TS$ zum 31.12.2014 + 400 TS$ Privatplazierung am 19.3.15 CashBurnRate = 460TS$. Wovon existieren die z.Zt.
Aus SEC filing zum 31.12.2014 The Corporation will require additional funds to pursue its operations as a going concern for the fiscal year ending December 31, 2015 and beyond, some of the funds of which would be used to conduct further research and development, schedule clinical testing, obtain regulatory approvals and the commercialization of its product candidates. The Corporation had available cash of approximately $632,272 and a working capital deficiency (excluding deferred revenue) of $580,375 as of December 31, 2014. Cash flows used in operations during 2014 were $5,515,479.
|